Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.30) by 16.67 percent. This is a 47.06 percent decrease over losses of $(0.17) per share from the same period last year. The company reported $2.170 million in sales this quarter. This is a 72.84 percent decrease over sales of $7.990 million the same period last year.